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Abstract

FDA to Create Drug Safety Board In February 2005, the Food and Drug Administration (FDA) announced that it will create a new independent Drug Safety
Oversight Board (DSB) to oversee the management of drug safety issues within
the Center for Drug Evaluation and Research (CDER). The FDA Commissioner
will appoint individuals from the FDA and medical experts from other Health and
Human Services agencies and government departments to the DSB, which also
will consult with other medical experts and patient and consumer group representatives. Additionally, the FDA is proposing a new “Drug Watch” web page
for emerging data and risk information, and anticipates an increased use of information sheets written for healthcare professionals and patients. Because of the
potential concerns associated with disseminating emerging information prior to
regulatory action, the agency has stated it will solicit public input. The FDA will
issue draft guidance on procedures and criteria for identifying drugs and information for the Drug Watch web page.
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In February 2005, the Food and Drug
Administration (FDA) announced that it
will create a new independent Drug Safety
Oversight Board (DSB) to oversee the
management of drug safety issues within the
Center for Drug Evaluation and Research
(CDER). The FDA Commissioner will appoint
individuals from the FDA and medical experts
from other Health and Human Services
agencies and government departments to
the DSB, which also will consult with other
medical experts and patient and consumer
group representatives. Additionally, the FDA
is proposing a new “Drug Watch” web page
for emerging data and risk information, and
anticipates an increased use of information
sheets written for healthcare professionals and
patients. Because of the potential concerns
associated with disseminating emerging
information prior to regulatory action,
the agency has stated it will solicit public
input. The FDA will issue draft guidance on
procedures and criteria for identifying drugs and
information for the Drug Watch web page.
The agency’s announcement falls on the heels
of earlier action also taken to address drug
safety concerns. In November 2004, Acting
FDA Commissioner Lester M. Crawford, D.V.M.,
Ph.D., announced that an Institute of Medicine
committee would study the effectiveness of
the US drug safety system and determine
if additional steps could be taken to learn
more about the side effects of drugs as they
are actually used. Dr. Crawford announced a
CDER pilot program to provide for a review
of differing professional opinions by FDA and
outside experts. The agency will also conduct
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workshops and advisory committee meetings
to discuss drug safety and risk management
issues, such as whether a safety concern alters
a drug’s risk to beneﬁt balance; whether the
agency should request that a sponsor conduct a
study to address an issue and, if so, what type of
study would be most appropriate; and whether
a ﬁnding is unique to one product or reﬂects a
drug class effect. These meetings are designed
to include a broad array of participants,
including experts from academia, the pharmaceutical industry and the healthcare community.
FDA Factsheet
FDA Statement

OVERHAUL OF EUROPE
Overhaul of EU Pharmaceutical Law
Nine years ago, the European Parliament
stated that in order for the EU to remain
competitive in the expanding European
and international non-proprietary markets,
measures should be introduced at the EU
level permitting generic pharmaceutical
companies to initiate experiments and
regulatory preparations prior to patent and
supplementary protection certiﬁcate expiration,
although the marketing of their products
should not be permitted until after this date.
As a result, by the end of November 2005,
the EU pharmaceutical legislative landscape
shall have witnessed signiﬁcant changes. One
new regulation and three new directives shall
enter into force effecting approximately 200
alterations, ranging from deﬁnition and administration clariﬁcations to substantial alterations
to the approval process for generic products
and follow-on biologicals (biosimilars).
Alterations to the regulatory powers of the
relevant authorities and a widening of the
mandatory scope of the centralized procedure
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shall take place, in addition to stricter pharmacovigilance and increased transparency.
These amendments shall permit the ﬁling of
abridged applications for generic medicinal
products eight years after EU approval of
the reference product (although marketing

“By the end of

is restricted until after ten years—or eleven
in the case of a new therapeutic indication of

November 2005, the

signiﬁcant clinical beneﬁt). The present reliance

EU pharmaceutical

generic medicinal product to one previously

legislative landscape

deﬁnition of a “generic medicinal product”—one

shall have witnessed

active substance composition, the same

signiﬁcant changes.”

Finally, the Committee for Human Medicinal

on the “essentially similar” test comparing a
authorized has been replaced with a codiﬁed
that has the same qualitative and quantitative
pharmaceutical form, and is bioequivalent.
Products technical guidelines must be taken into
account by marketing authorization applicants.
Regulation on Medicinal Products for
Human and Veterinary Use
Directive on Medicinal Products for Human Use
Directive on Veterinary Medicinal Products
Directive on Medicinal Products for
Human Use (Herbal Products)

ECJ Rulings Erode Data Exclusivity
While the new EU Pharmaceutical Package

“Potentially sweeping
changes to fundamental
laws of the US
patent system are
on the horizon.”

outlined above clariﬁes the deﬁnition of a
generic medicinal product for the purpose of
abridged applications ﬁled after the provisions
enter into force, present applications rely on
the outcome of two recent European Court
of Justice (ECJ) rulings, the joint effect of which
has been to further erode the reliance on
regulatory data protection afforded to newly
authorized medicines. In separate references
concerning Eli Lilly and SmithKline Beecham,
the ECJ held that “essentially similar” is satisﬁed
respectively, by a medicinal product differing
only in pharmaceutical form and one sharing
the same therapeutic moiety, but differing
as to the identity of its combined salt.
Approved Prescription Services v. UK Licensing
Authority (Interested Party: Eli Lilly)
SmithKline Beecham v. Laegemiddelstyrelsen
(Interveners: Synthon and Genthon)

INTELLECTUAL PROPERTY
UNITED STATES
Life Cycle Management and Proposed
Patent Harmonization
The growth of the generic drug industry began
with the enactment of the Hatch-Waxman Act
in 1984. With the rise of generic competition,
innovator drug companies embarked on
creative patent strategies, tactical licensing
arrangements and litigation intended to protect
their market exclusivity of brand name drugs.
All of these considerations—together with
an understanding of the complex body of
statutes, regulations and court decisions that
control practice under the Hatch-Waxman
Act—are vital in mapping a course for life cycle
management of a drug product. Reﬁnements
and changes to the Hatch-Waxman Act
continue to inﬂuence innovator drug companies’
strategies for product life cycle management.
The Medicare Prescription Drug, Improvement
and Modernization Act of 2003 (Medicare
Amendment) made a number of important
changes to the Hatch-Waxman Act, including
limiting the number of automatic 30-month
stays to one and eliminating the district court
decision trigger for 180-day generic marketing
exclusivity. Prior to the Medicare Amendment,
the FDA implemented guidelines clarifying what
patents could be listed in the Orange Book.
Implementation of strategies for product life cycle
management starts long before the expiration
of the basic patent covering the innovator drug.
But the principal strategy of maintaining patent
protection through a stream of patentable
product innovations faces the constant hurdle of
shifting patent laws and regulations. Potentially
sweeping changes to fundamental laws of the US
patent system are on the horizon. The National
Academies’ Board on Science, Technology
and Economic Policy (STEP) and the Federal
Trade Commission (FTC) issued reports with
recommendations on modernizing US patent
law. A singularly important recommendation
of STEP is to seek greater harmonization
between US patent laws and those of other
countries, including changing US patent law
to guarantee the right to patent to the ﬁrst
inventor who ﬁles for a patent, and creating a
window after a patent is issued for an opposition
procedure that would permit the correction
of any mistake made in granting the patent.
STEP Report
FTC Report
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EUROPE

Introduction of EU “Bolar” Provision

Patent Claim Construction Guidance
from the House of Lords

By the end of 2005, all EU Member States
must have implemented the EU Pharmaceutical
Regulation and Directives Package. This shall
permit pre-patent-expiration development
work, registration and generic approval, and
non-infringing testing of patented medicines.

The October 2004 Kirin-Amgen v. TKT judgment
is signiﬁcant for intellectual property practitioners
operating in biotech and high-tech industries.
Adjudicating on a European patent relating to
inter-cellular production of erythropoietin, the
House of Lords conducted a detailed review of
the law on claim construction and conﬁrmed
that the principle of “purposive construction”
was in accordance with the European Patent
Convention. Their lordships continued to
state that this did not, however, mean that the
rigid application of certain formulations of this
principle were appropriate in the biotech and
high-tech ﬁelds. The critical question was what
the skilled man would have understood as being
intended by the language used in the claim.
Kirin-Amgen v.TKT (2004)

Interim Injunctions against Generics Refused
In two separate applications during the close
of 2004, the UK High Court refused interim
injunctions against generic pharmaceutical
companies alleged to infringe European patents
for crystalline clarithromycin and the cancer
treatment paclitaxel, respectively. The ﬁrst
was refused on the basis of the “manifest
weakness of the patent” (although the court
noted that had the facts been contrary, the
“big unquantiﬁable” loss represented by “price
erosion” would have outweighed the “little
unquantiﬁable” loss represented by the generic’s
“ﬁve months’ advantage” in the market). The
second was refused because of incomplete
evidence and the absence of sufﬁcient threat and
damage to require urgent court intervention.
Abbott v. Ranbaxy (2004)
Mayne v.Teva (2004)

German Patent Act Amendment
Effective on February 28, 2005, the German
Patent Act shall ﬁnally be updated to
accord with the European Directive on the
legal protection of biotech inventions. Of
particular interest, the German legislature
has decided that only inventions regarding
precisely described commercial applications
of human gene sequences and their corresponding protein may be patentable.
Directive on Legal Protection of Biotech Inventions
German Patent Act

ANTITRUST/COMPETITION
UNITED STATES
FTC Supports Generic’s Petition to Expand
Availability of Declaratory Judgment Actions
The US Federal Trade Commission has ﬁled a
brief in support of the efforts of a generic drug
manufacturer (Teva) to seek further review of a
decision of the Court of Appeals for the Federal
Circuit, which blocked its effort to market an
alternative to the antidepressant drug Zoloft and
sided with Zoloft’s manufacturer, Pﬁzer. Under
the Hatch-Waxman Act—a complex statute
which governs the rights of manufacturers of
brand and generic drugs—the ﬁrst generic
manufacturer to ﬁle a “Paragraph IV certiﬁcation”
challenging the brand drug manufacturer’s
patent obtains a period of 180 days of marketing
“exclusivity,” during which the FDA may not
approve subsequent generic versions of the
drug. However, the period does not begin to
run until the ﬁrst day of commercial marketing
by the generic manufacturer or the date of a
court decision ﬁnding the patent is invalid or
not infringed. Thus, a “bottleneck” may be
created where the generic manufacturer and
the patent owner reach a settlement under
which the generic manufacturer agrees to
delay market entry in exchange for a license
to the patent. The generic manufacturer
still has the right to 180 days of exclusivity,
but the period does not begin to run and
subsequent generics thus cannot be approved.

“The critical question was
what the skilled man
would have understood
by the language
used in the claim.”

In this case, Pﬁzer reached such a settlement with
Ivax (the ﬁrst generic manufacturer to challenge
its patent), and Teva (the second generic
manufacturer) sought to break the bottleneck by
ﬁling its own Paragraph IV certiﬁcation. When
Pﬁzer did not sue Teva, the company then sought
a declaratory judgment that Pﬁzer’s patent was
invalid or not infringed. However, the lower court
held that there was no “actual controversy”
between the parties (which is required to bring
a declaratory judgment suit) because there was
no present threat that Pﬁzer would sue Teva
for infringement. The appellate court upheld
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the decision and Teva is now seeking rehearing
and/or review before the full “en banc” court.
Essentially, the FTC has sided with Teva on
public policy grounds, arguing that, in this
context, declaratory judgment actions should
be allowed to proceed because they “could
play an important role in furthering competitive
pharmaceutical markets and in lowering
healthcare costs.” The FTC has previously
supported challenges (and has brought them
itself) to what it believes to be abuses of the
Hatch-Waxman Act’s provisions that impede
competition by generic manufacturers.

The opinion of the Advocate-General is not
binding on the European Court of Justice, whose
ﬁnal judgment is still awaited, although such
opinions are upheld in a large majority of cases.
Syfait v. GlaxoSmithKline (2004)

FTC Brief

EUROPE
Advocate-General Opinion on Supply
Restrictions That Limit Parallel Trade
In October 2004, Advocate-General Jacobs
delivered an important opinion in Syfait v.
GlaxoSmithKline. This was a reference to the
European Court of Justice from the Greek
Competition Commission on the issue of
whether the protection of legitimate commercial
interests can justify a restriction of supply by
a dominant pharmaceutical company, which
is designed to limit parallel trade. AdvocateGeneral Jacobs considered that a refusal to
supply does not automatically amount to
an abuse of a dominant position within the
meaning of Article 82 EC simply because the
measure is designed to restrict parallel trade.
Instead, he considered that a supply restriction
that limits parallel trade can be objectively
justiﬁed in the “highly speciﬁc” context of
the European pharmaceutical industry as:
(1) normal competitive conditions do not
exist in the European pharmaceutical
market due to the high level of regulation
which affects price and distribution;
(2) incentives for dominant companies to
innovate and invest in R&D would be
harmed if prices to wholesalers across the
EU were effectively reduced to the lowest
national price charged to wholesalers; and
(3) parallel trade in pharmaceuticals mainly
beneﬁts wholesalers, rather than purchasers.
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